A phase 1/2 study of ALE-P02
Latest Information Update: 09 Oct 2024
At a glance
- Drugs ALE P02 (Primary)
- Indications Squamous cell cancer
- Focus Adverse reactions
- 09 Oct 2024 New trial record
- 02 Oct 2024 According to an Alentis Therapeutics media release, the U.S. Food & Drug Administration (FDA) cleared an IND application for ALE.P02 and this phase 1/2 study is expected to start during the first quarter of 2025.